PMID- 33964996
OWN - NLM
STAT- MEDLINE
DCOM- 20220103
LR  - 20220103
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 76
IP  - 5
DP  - 2021 May 1
TI  - Anisodamine ameliorates ischemia/reperfusion-induced renal injury in rats through 
      activation of the extracellular signal-regulated kinase (ERK) pathway and 
      anti-apoptotic effect.
PG  - 220-224
LID - 10.1691/ph.2021.1302 [doi]
AB  - Anisodamine exerts significant protective effect on ischemia/reperfusion (I/R) 
      injury in various organs. However, little is known about the mechanisms of 
      anisodamine in renal I/R injury. Activation of extracellular regulated protein 
      kinases (ERK) pathway promotes the repair of renal epithelial cells following 
      oxidant injury. The present study investigated whether the renoprotective role of 
      anisodamine against renal I/R injury in rats was associated with the activation 
      of ERK signaling pathway. Male Sprague-Dawley (SD) rats were separated into the 
      following groups: Sham-operated group, I/R group, anisodamine-treated group, 
      PD98059 (MEK-1/ERK inhibitor)-treated group and anisodamine plus PD98059-treated 
      group. A rat model of renal I/R was established by excising the right kidney and 
      then clamping the left renal pedicle for 45 min followed by reperfusion for 24 h. 
      Serum and renal tissue samples were obtained for assays of the associated 
      morphological, molecular and biochemical parameters. Treatment with anisodamine 
      ameliorated renal I/R injury, as evidenced by improvements of renal histology and 
      kidney function, a decrease in paller's score and apoptosis index. Anisodamine 
      also upregulated the phosphorylation levels of ERK1/2 and its downstream targets, 
      including 90 ribosomal S6 kinase (p90rsk) and Bad, as well as the expression of 
      antiapoptotic Bcl-2 protein, downregulated the expression levels of proapoptotic 
      proteins Bax and cleaved-caspase-3, whereas these effects were greatly abolished 
      by administration of PD98059. In conclusion, the results suggest that anisodamine 
      prevents renal I/R injury in rats as a result of an activation of the ERK 
      signaling pathway and anti-apoptotic properties.
FAU - Zhang, Shu
AU  - Zhang S
AD  - Department of Pharmacology, Jiangsu, China.
FAU - Xu, Xianzhi
AU  - Xu X
AD  - School of Stomatology, Xuzhou Medical University, Jiangsu, China.
FAU - Huang, Yuanhong
AU  - Huang Y
AD  - School of Stomatology, Xuzhou Medical University, Jiangsu, China.
FAU - Sun, Siyuan
AU  - Sun S
AD  - School of Stomatology, Xuzhou Medical University, Jiangsu, China.
FAU - Jin, Chengqi
AU  - Jin C
AD  - School of Stomatology, Xuzhou Medical University, Jiangsu, China.
FAU - Ji, Hao
AU  - Ji H
AD  - School of Stomatology, Xuzhou Medical University, Jiangsu, China.
FAU - Sun, Dong
AU  - Sun D
AD  - Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China;, Email: Sundong126@yahoo.com.
FAU - Xia, Anzhou
AU  - Xia A
AD  - Department of Pharmacology, Jiangsu, China;, Email: xiaanzhou@xzhmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Flavonoids)
RN  - 0 (Solanaceous Alkaloids)
RN  - 01343Q8EL8 (anisodamine)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
MH  - Acute Kidney Injury/*drug therapy/pathology
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Apoptosis Regulatory Proteins/metabolism
MH  - Epithelial Cells/drug effects
MH  - Flavonoids/pharmacology
MH  - Kidney/drug effects/metabolism
MH  - MAP Kinase Signaling System/*drug effects
MH  - Male
MH  - Models, Animal
MH  - Phosphorylation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reperfusion Injury/*drug therapy/pathology
MH  - Signal Transduction/drug effects
MH  - Solanaceous Alkaloids/*pharmacology
EDAT- 2021/05/10 06:00
MHDA- 2022/01/04 06:00
CRDT- 2021/05/09 20:24
PHST- 2021/05/09 20:24 [entrez]
PHST- 2021/05/10 06:00 [pubmed]
PHST- 2022/01/04 06:00 [medline]
AID - 10.1691/ph.2021.1302 [doi]
PST - ppublish
SO  - Pharmazie. 2021 May 1;76(5):220-224. doi: 10.1691/ph.2021.1302.